BMS-751324

Cat. No.:	HY-18759
CAS No.:	948842-66-8
Molecular Formula:	$C_{32}H_{35}N_6O_{10}P$
Molecular Weight:	694.63
Target:	p38 MAPK; TNF Receptor
Pathway:	MAPK/ERK Pathway; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model[1].
In Vitro	BMS-751324 (10 μM; 0-60 min) can be hydrolyzed by alkaline phosphatase (human placental ALP), instead of esterase [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	BMS-751324 (1 mg/kg, 3mg/kg; p.o.; twice daily for 1 week) inhibits paw swelling in rat adjuvant arthritis model, as well as (1 mg/kg, 3mg/kg; p.o.; single dose) inhibiting LPS-induced TNFα production[1]. BMS-751324 (1 mg/kg-100 mg/kg for rat, 10 or 30 mg/kg for monkey with 5 mL/kg of methocel suspension; p.o.; single dose) exhibits a bio-conversion in animals[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Liu C, et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo [1, 2-f][1, 2, 4] triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases[J]. Journal of medicinal chemistry, 2010, 53(18): 6629-6639.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA